Imidazopyridazines as Akt kinase inhibitors

US9604989B2 · kind B2 · utility

Assignees

• Bayer Intellectual Property GmbH · DE
• Bayer Pharma Aktiengesellschaft · DE

Inventors

• Lars Bärfacker · Oberhausen, DE
• William Scott · Guilford, US
• Andrea Hägebarth · Berlin, DE
• Stuart Ince · Berlin, DE
• Hartmut Rehwinkel · Berlin, DE
• Oliver Politz · Panketal, DE
• Roland Neuhaus · Berlin, DE
• Hans Briem · Bremen, DE
• Ulf Bömer · Glienicke, DE

Key dates

• Filing date: Jul 6, 2015
• Grant date: Mar 28, 2017
• Expiry date: Jul 6, 2035

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61P43/00
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention relates to a method for the treatment of a cancer that is sensitive to Pi3K/Akt pathway inhibition by administering a therapeutically effective amount of a compound of formula (I)